Tilray Acquires Lyphe, Dispenses 150,000 Units; BrewDog Cashflow Positive by 2027
Tilray acquired UK-based Lyphe Group, which has dispensed 150,000 units and treated 16,000 patients, creating its first fully integrated medical cannabis and pharmaceutical distribution platform. Weeks after its BrewDog purchase, Tilray stabilized volumes, aims to rebuild valuation above $1 billion and expects the beer unit to turn cashflow positive in 2027.
1. Tilray Acquires Lyphe to Expand UK Medical Platform
Tilray completed its acquisition of the Lyphe Group, integrating a UK-based medical cannabis clinic and digital pharmacy into its existing operations. Lyphe has dispensed approximately 150,000 units and treated over 16,000 patients, establishing a fully vertical ecosystem that combines cultivation, clinical services and pharmaceutical distribution across the UK.
2. BrewDog Stabilization and Growth Plans
Six weeks after acquiring BrewDog, Tilray has stabilized brewing volumes and service levels while onboarding new distribution partners in key markets. The company is targeting a valuation rebound above $1 billion for BrewDog and expects the beer business to achieve positive cashflow by 2027, supported by investments to modernize its brewpub network.
3. Hi*Ball Energy Launch and U.S. Rescheduling Positioning
Tilray plans to launch Hi*Ball Energy in the UK in May, entering the fast-growing functional beverage category and leveraging its existing distribution infrastructure. Meanwhile, the company is monitoring potential U.S. cannabis rescheduling and engaging with regulators to secure early positioning in the domestic medical cannabis market.